• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

组蛋白去乙酰化酶5抑制剂作为治疗患乳腺癌的极年轻女性的潜在疗法

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.

作者信息

Oltra Sara S, Cejalvo Juan Miguel, Tormo Eduardo, Albanell Marta, Ferrer Ana, Nacher Marta, Bermejo Begoña, Hernando Cristina, Chirivella Isabel, Alonso Elisa, Burgués Octavio, Peña-Chilet Maria, Eroles Pilar, Lluch Ana, Ribas Gloria, Martinez María Teresa

机构信息

INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain.

Biomedical Research Centre Network in Cancer (CIBERONC), 46010 Valencia, Spain.

出版信息

Cancers (Basel). 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412.

DOI:10.3390/cancers12020412
PMID:32050699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7072585/
Abstract

BACKGROUND

Breast cancer in very young women (BCVY) defined as <35 years old, presents with different molecular biology than in older patients. High expression has been associated with poor prognosis in breast cancer (BC) tissue. We aimed to analyze expression in BCVY and older patients and their correlation with clinical features, also studying the potential of HDAC5 inhibition in BC cell lines.

METHODS

expression in 60 BCVY and 47 older cases were analyzed by qRT-PCR and correlated with clinical data. The effect of the HDAC5 inhibitor, LMK-235, was analyzed in BC cell lines from older and young patients. We performed time and dose dependence viability, migration, proliferation, and apoptosis assays.

RESULTS

Our results correlate higher expression with worse prognosis in BCVY. However, we observed no differences between expression and pathological features. Our results showed greatly reduced progression in BCVY cell lines and also in all triple negative subtypes when cell lines were treated with LMK-235.

CONCLUSIONS

In BCVY, we found higher expression of HDAC5. Overexpression of in BCVY correlates with lower survival rates. LMK-235 could be a potential treatment in BCVY.

摘要

背景

非常年轻女性的乳腺癌（BCVY）定义为年龄小于35岁，其呈现出与老年患者不同的分子生物学特征。在乳腺癌（BC）组织中高表达与预后不良相关。我们旨在分析BCVY和老年患者中的表达情况及其与临床特征的相关性，同时研究HDAC5抑制在BC细胞系中的潜力。

方法

通过qRT-PCR分析60例BCVY和47例老年病例中的表达情况，并与临床数据相关联。在老年和年轻患者的BC细胞系中分析HDAC5抑制剂LMK-235的作用。我们进行了时间和剂量依赖性的活力、迁移、增殖和凋亡测定。

结果

我们的结果表明，BCVY中较高的表达与较差的预后相关。然而，我们未观察到表达与病理特征之间的差异。我们的结果显示，当用LMK-235处理细胞系时，BCVY细胞系以及所有三阴性亚型的进展均大大降低。

结论

在BCVY中，我们发现HDAC5表达较高。BCVY中HDAC5的过表达与较低的生存率相关。LMK-235可能是BCVY的一种潜在治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/edb47af8992f/cancers-12-00412-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/0cac93d08260/cancers-12-00412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/bbe895c82c7c/cancers-12-00412-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/ac2a1adfe4f3/cancers-12-00412-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/2f3be381a0c3/cancers-12-00412-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/edb47af8992f/cancers-12-00412-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/0cac93d08260/cancers-12-00412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/bbe895c82c7c/cancers-12-00412-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/ac2a1adfe4f3/cancers-12-00412-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/2f3be381a0c3/cancers-12-00412-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8489/7072585/edb47af8992f/cancers-12-00412-g005.jpg

相似文献

1
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.组蛋白去乙酰化酶5抑制剂作为治疗患乳腺癌的极年轻女性的潜在疗法
Cancers (Basel). 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412.
2
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.组蛋白去乙酰化酶5（HDAC5）是一种潜在的治疗靶点和预后生物标志物，可促进人类乳腺癌的增殖、侵袭和迁移。
Oncotarget. 2016 Jun 21;7(25):37966-37978. doi: 10.18632/oncotarget.9274.
3
Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator.西班牙队列中非常年轻患者的乳腺癌：年龄作为独立的不良预后指标
Breast Cancer (Auckl). 2019 Feb 20;13:1178223419828766. doi: 10.1177/1178223419828766. eCollection 2019.
4
Acceleration in the DNA methylation age in breast cancer tumours from very young women.乳腺癌肿瘤中非常年轻女性的 DNA 甲基化年龄加速。
Sci Rep. 2019 Oct 18;9(1):14991. doi: 10.1038/s41598-019-51457-6.
5
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.LMK-235 对胰腺神经内分泌肿瘤细胞的 IIA 类组蛋白去乙酰化酶的抑制作用。
Int J Mol Sci. 2018 Oct 12;19(10):3128. doi: 10.3390/ijms19103128.
6
Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women.miRNA 启动子甲基化失调鉴定 miR124-2 作为极年轻女性乳腺癌的生存标志物。
Sci Rep. 2018 Sep 26;8(1):14373. doi: 10.1038/s41598-018-32393-3.
7
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.组蛋白去乙酰化酶5（HDAC5）与赖氨酸特异性去甲基化酶1（LSD1）的功能性相互作用促进乳腺癌进展。
Oncogene. 2017 Jan 5;36(1):133-145. doi: 10.1038/onc.2016.186. Epub 2016 May 23.
8
Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells.组蛋白去乙酰化酶 5 促进肺癌细胞的增殖和侵袭。
Oncol Rep. 2018 Oct;40(4):2224-2232. doi: 10.3892/or.2018.6591. Epub 2018 Jul 24.
9
AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.AR-42通过抑制HDAC5诱导人肝癌细胞凋亡。
Oncotarget. 2016 Apr 19;7(16):22285-94. doi: 10.18632/oncotarget.8077.
10
HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.组蛋白去乙酰化酶5通过上调DLL4表达促进结肠癌细胞增殖。
Int J Clin Exp Med. 2015 Apr 15;8(4):6510-6. eCollection 2015.

引用本文的文献

1
DHX9-mediated epigenetic silencing of BECN1 contributes to impaired autophagy and tumor progression in breast cancer via recruitment of HDAC5.DHX9介导的BECN1表观遗传沉默通过招募HDAC5导致乳腺癌中自噬受损和肿瘤进展。
Cell Death Dis. 2025 Jul 14;16(1):524. doi: 10.1038/s41419-025-07847-y.
2
The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications.组蛋白翻译后修饰在癌症及癌症免疫中的作用：功能、机制及治疗意义
Front Immunol. 2024 Nov 15;15:1495221. doi: 10.3389/fimmu.2024.1495221. eCollection 2024.
3
Association of changes in expression of and genes after drug treatment with cancer cell line sensitivity to kinase inhibitors.

本文引用的文献

1
Acceleration in the DNA methylation age in breast cancer tumours from very young women.乳腺癌肿瘤中非常年轻女性的 DNA 甲基化年龄加速。
Sci Rep. 2019 Oct 18;9(1):14991. doi: 10.1038/s41598-019-51457-6.
2
Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women.miRNA 启动子甲基化失调鉴定 miR124-2 作为极年轻女性乳腺癌的生存标志物。
Sci Rep. 2018 Sep 26;8(1):14373. doi: 10.1038/s41598-018-32393-3.
3
The biological significance of histone modifiers in multiple myeloma: clinical applications.
药物处理后 和 基因表达变化与激酶抑制剂对癌细胞系敏感性的关系。
Epigenetics. 2024 Dec;19(1):2309824. doi: 10.1080/15592294.2024.2309824. Epub 2024 Feb 18.
4
HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells.组蛋白去乙酰化酶11与乳腺癌预后相关，并抑制乳腺癌细胞的侵袭和增殖。
Int J Clin Exp Pathol. 2023 Jul 15;16(7):172-183. eCollection 2023.
5
HDAC-an important target for improving tumor radiotherapy resistance.组蛋白去乙酰化酶——提高肿瘤放疗抗性的重要靶点。
Front Oncol. 2023 Jul 12;13:1193637. doi: 10.3389/fonc.2023.1193637. eCollection 2023.
6
HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway.组蛋白去乙酰化酶5介导的黑色素瘤抗原基因通过PI3K/AKT/mTOR信号通路调控喉鳞状细胞癌的增殖、迁移、侵袭和上皮-间质转化。
Open Med (Wars). 2023 Mar 9;18(1):20230665. doi: 10.1515/med-2023-0665. eCollection 2023.
7
promotes lung adenocarcinoma progression by upregulating histone deacetylase 5.通过上调组蛋白去乙酰化酶5促进肺腺癌进展。
Front Microbiol. 2023 Feb 1;14:1121863. doi: 10.3389/fmicb.2023.1121863. eCollection 2023.
8
Histone deacetylase 4 and 5 translocation elicited by microsecond pulsed electric field exposure is mediated by kinase activity.微秒级脉冲电场暴露引发的组蛋白去乙酰化酶4和5易位由激酶活性介导。
Front Bioeng Biotechnol. 2022 Nov 17;10:1047851. doi: 10.3389/fbioe.2022.1047851. eCollection 2022.
9
High expression correlates with a poor prognosis and the tumor immune microenvironment in gastric cancer.高表达与胃癌的不良预后及肿瘤免疫微环境相关。
Ann Transl Med. 2022 Sep;10(18):990. doi: 10.21037/atm-22-4325.
10
Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.组蛋白去乙酰化酶5在癌症治疗中的功能及临床应用洞察
Front Oncol. 2021 Jun 10;11:661620. doi: 10.3389/fonc.2021.661620. eCollection 2021.
组蛋白修饰酶在多发性骨髓瘤中的生物学意义：临床应用。
Blood Cancer J. 2018 Aug 22;8(9):83. doi: 10.1038/s41408-018-0119-y.
4
Effects of novel HDAC inhibitors on urothelial carcinoma cells.新型 HDAC 抑制剂对尿路上皮癌细胞的影响。
Clin Epigenetics. 2018 Jul 31;10(1):100. doi: 10.1186/s13148-018-0531-y.
5
The potential contribution of dietary factors to breast cancer prevention.饮食因素对预防乳腺癌的潜在作用。
Eur J Cancer Prev. 2017 Sep;26(5):385-395. doi: 10.1097/CEJ.0000000000000406.
6
Histone Deacetylase Inhibitors as Anticancer Drugs.组蛋白去乙酰化酶抑制剂作为抗癌药物
Int J Mol Sci. 2017 Jul 1;18(7):1414. doi: 10.3390/ijms18071414.
7
Correction: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.更正：HDAC5是一种潜在的治疗靶点和预后生物标志物，可促进人乳腺癌的增殖、侵袭和迁移。
Oncotarget. 2017 May 2;8(18):30619-30620. doi: 10.18632/oncotarget.17542.
8
Breast cancer in young women: an overview.年轻女性乳腺癌概述
Updates Surg. 2017 Sep;69(3):313-317. doi: 10.1007/s13304-017-0424-1. Epub 2017 Mar 4.
9
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.胰腺神经内分泌肿瘤中组蛋白去乙酰化酶的综合免疫组化分析：HDAC5作为临床预后不良的预测指标
Hum Pathol. 2017 Jul;65:41-52. doi: 10.1016/j.humpath.2017.02.009. Epub 2017 Feb 22.
10
Clinical Toxicities of Histone Deacetylase Inhibitors.组蛋白去乙酰化酶抑制剂的临床毒性
Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. doi: 10.3390/ph3092751.